Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Forrest W Williard"'
Autor:
Andrew M. Fleming, Benjamin W. Deschner, Forrest W. Williard, Justin A. Drake, Ari Vanderwalde, Joanne Xiu, Bradley G. Somer, Danny Yakoub, Miriam W. Tsao, Evan S. Glazer, Paxton V. Dickson, David Shibata, Philip A. Philip, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, W. Michael Korn, Heinz‐Josef Lenz, Jeremiah L. Deneve
Publikováno v:
Journal of Surgical Oncology. 127:815-822
Autor:
Philip A. Philip, Benjamin W. Deschner, Joanne Xiu, John L. Marshall, Michael Gary Martin, Miriam W. Tsao, Matthew K Stein, Heinz-Josef Lenz, Forrest W Williard, Evan S. Glazer, Jeremiah L. Deneve, Danny Yakoub, Axel Grothey, W. Michael Korn, David Shibata, Anthony F. Shields, Paxton V. Dickson, Jimmy J. Hwang
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES: Peritoneal metastases (PM) from primary colorectal cancer (pCRC) are associated with poor outcomes; however, molecular differences are not well defined. METHODS: We compared unpaired tumor profiles of patients with pCRC and
Autor:
Danny Yakoub, Richard M. Goldberg, Michael Gary Martin, Axel Grothey, Paxton V. Dickson, Jimmy J. Hwang, Evan S. Glazer, W. Michael Korn, David Shibata, Anthony F. Shields, Matthew K Stein, Philippe Prouet, Joanne Xiu, Jeffrey Owsley, Forrest W Williard, Jeremiah L. Deneve, Heinz-Josef Lenz
Publikováno v:
Journal of Clinical Oncology. 37:4053-4053
4053 Background: PM from GC or GEJ portend a poor prognosis and molecular differences are ill defined. Methods: We compared genomic profiles of primary (P) GC and GEJ with PM patients (pts) and other metastases (OM) sent to Caris Life Sciences. Testi
Autor:
Matthew K Stein, Evan S. Glazer, Forrest W Williard, Jeremiah L. Deneve, Paxton V. Dickson, Benjamin W. Deschner, Michael Gary Martin, Miriam W. Tsao
Publikováno v:
Journal of Clinical Oncology. 37:498-498
498 Background: PM from CRC are associated with poor outcomes; however, molecular differences are not defined. Methods: We compared tumor profiles of pCRC and PM patients (pts) from Caris Life Sciences. Testing included next-generation sequencing (NG